Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
J Pharmacol Exp Ther ; 357(3): 554-61, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-27048659

RESUMEN

BI 1002494 [(R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6]napthyridin-5-yloxy]-ethyl}pyrrolidin-2-one] is a novel, potent, and selective spleen tyrosine kinase (SYK) inhibitor with sustained plasma exposure after oral administration in rats, which qualifies this molecule as a good in vitro and in vivo tool compound. BI 1002494 exhibits higher potency in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation (IC50 = 115 nM) compared with B-cell receptor-mediated activation of B cells (IC50 = 810 nM). This may be explained by lower kinase potency when the physiologic ligand B-cell linker was used, suggesting that SYK inhibitors may exhibit differential potency depending on the cell type and the respective signal transduction ligand. A 3-fold decrease in potency was observed in rat basophils (IC50 = 323 nM) compared with human basophils, but a similar species potency shift was not observed in B cells. The lower potency in rat basophils was confirmed in both ex vivo inhibition of bronchoconstriction in precision-cut rat lung slices and in reversal of anaphylaxis-driven airway resistance in rats. The different cellular potencies translated into different in vivo efficacy; full efficacy in a rat ovalbumin model (that contains an element of mast cell dependence) was achieved with a trough plasma concentration of 340 nM, whereas full efficacy in a rat collagen-induced arthritis model (that contains an element of B-cell dependence) was achieved with a trough plasma concentration of 1400 nM. Taken together, these data provide a platform from which different estimates of human efficacious exposures can be made according to the relevant cell type for the indication intended to be treated.


Asunto(s)
Linfocitos B/efectos de los fármacos , Linfocitos B/enzimología , Basófilos/efectos de los fármacos , Basófilos/enzimología , Naftiridinas/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Pirrolidinas/farmacología , Pirrolidinonas/farmacología , Quinasa Syk/antagonistas & inhibidores , Administración Oral , Animales , Humanos , Masculino , Mastocitos/efectos de los fármacos , Mastocitos/enzimología , Naftiridinas/administración & dosificación , Inhibidores de Proteínas Quinasas/administración & dosificación , Pirrolidinas/administración & dosificación , Pirrolidinonas/administración & dosificación , Ratas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA